Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of “Hold” by Brokerages

Design Therapeutics, Inc. (NASDAQ:DSGN) has earned a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.60.

A number of equities research analysts have commented on the stock. Piper Sandler raised shares of Design Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $6.00 to $12.00 in a report on Tuesday, May 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a research note on Wednesday, March 20th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Design Therapeutics in a research note on Wednesday, March 20th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. BML Capital Management LLC bought a new position in Design Therapeutics during the 4th quarter worth approximately $2,728,000. Pale Fire Capital SE bought a new position in Design Therapeutics during the 4th quarter worth approximately $28,000. Barclays PLC boosted its stake in Design Therapeutics by 353.1% during the 3rd quarter. Barclays PLC now owns 71,678 shares of the company’s stock worth $170,000 after acquiring an additional 55,858 shares during the last quarter. RTW Investments LP boosted its stake in Design Therapeutics by 60.8% during the 3rd quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock worth $5,931,000 after acquiring an additional 949,955 shares during the last quarter. Finally, Algert Global LLC boosted its stake in Design Therapeutics by 83.3% during the 3rd quarter. Algert Global LLC now owns 35,620 shares of the company’s stock worth $84,000 after acquiring an additional 16,190 shares during the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Up 3.7 %

Shares of NASDAQ:DSGN opened at $3.35 on Friday. Design Therapeutics has a 12 month low of $1.94 and a 12 month high of $8.31. The company’s 50-day moving average price is $3.94 and its two-hundred day moving average price is $3.22. The firm has a market cap of $189.24 million, a P/E ratio of -3.19 and a beta of 1.87.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.08. As a group, equities analysts predict that Design Therapeutics will post -1.02 earnings per share for the current fiscal year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.